This article is more than 5 years old. Information may no longer be current.
VIDEO: CPX-351 demonstrates survival advantage in patients with secondary AML
The standard treatment for acute myeloid leukemia over the past few decades has been standard-dose cytarabine plus anthracycline, but, according to Eunice S. Wang, MD, chief of the Leukemia Service at Roswell Park Cancer Institute, there has been a recent improvement in that standard-of-care chemotherapy regimen.
In this video, Wang discusses the results from a phase 3 study that demonstrated CPX-351 (Vyxeos, Celator) — a liposomal formulation of cytarabine and daunorubicin (5:1) — prolonged OS and EFS in patients with high-risk secondary acute myeloid leukemia and appeared to reduce toxicity.
“We’re hoping to see this agent on the market later this year for treatment of that very difficult [to treat] patient population,” she said.
In addition, Wang discusses the effectiveness of crenolanib (CP-868-596, Arog Pharmaceuticals) – a highly-potent FLT3 inhibitor – which demonstrated significant efficacy in patients with multiple relapsed FLT3-mutated AML.
“The field of FLT3 inhibitor therapy is going to be exploding,” she said. “We’re going to be seeing improvements in standard “7 + 3” reduction and we’re seeing advances in the treatment of our elderly patients with AML.”